Takeda Pharmaceutical CO LTD

Lauren Rusckowski Duprey, Chief Transformation Officer of Takeda Pharmaceutical Co Ltd, sold 34,535 shares of common stock on September 14, 2026 for $18.54 per share.

Andrew Stewart Plump, President, R&D and a Director of Takeda Pharmaceutical Co Ltd, sold 116,191 shares of common stock on September 2, 2026 for $18.49 per share.

Andrew Stewart Plump, President, R&D and a Director of Takeda Pharmaceutical Co Ltd, sold 19,651 shares of common stock on August 19, 2026 for $18.49 per share.

Nicola Deidre Petal Greenway, Chief Human Resources Officer of Takeda Pharmaceutical Co Ltd, sold 12,980 shares of common stock on August 18, 2026 for $18.11 per share.

Awny Samaan Botros Farajallah, Chief Medical Officer of Takeda Pharmaceutical Co Ltd, sold 14,006 shares of common stock on August 10, 2026 for $17.10 per share.

Ramy Riad Ahmed Ibrahim, President, PDT BU of Takeda Pharmaceutical Co Ltd, sold 7,277 shares of common stock on August 10, 2026 for $17.10 per share.

Takeda Pharmaceutical Co Ltd disclosed its Q3 2025 equity portfolio, totaling $16.37 million across nine distinct positions, as detailed in its latest 13F-HR filing.

Takeda Pharmaceutical Co Ltd filed its quarterly 13F-HR report, revealing $19.55 million in equity holdings across 12 companies as of June 30, 2025.

Takeda Pharmaceutical Co. Ltd. reports its Q1 2025 holdings, revealing investments in various biotech and pharmaceutical companies.

Takeda Pharmaceutical Co. Ltd. reports its holdings as of September 30, 2024, in a Form 13F filing with the SEC, revealing investments in various biotech and pharmaceutical companies.

Takeda Pharmaceutical Co. Ltd. reports its Q2 2024 holdings, revealing significant investments in various biotech and pharmaceutical companies.

Takeda Pharmaceutical Co. Ltd. reveals its equity holdings as of March 31, 2024, showcasing a diverse portfolio of investments in various biotechnology and pharmaceutical companies.

Hillevax, Inc. has completed its merger with XRA 4 Corp., a subsidiary of XOMA Royalty Corporation, ceasing to be a publicly traded company.

Takeda Pharmaceutical Company Limited and its subsidiary Takeda Pharmaceuticals U.S.A., Inc. have filed an amendment to their beneficial ownership of Ovid Therapeutics Inc., reporting an aggregate stake of 12.3%.